Interferon Levels Explain mRNA Vaccine Side Effects
Analysis based on 6 articles · First reported Sep 17, 2026 · Last updated Sep 20, 2026
The study is a scientific advance that could inform future vaccine design, potentially benefiting vaccine developers such as Moderna by supporting next-generation products with improved tolerability. Near-term market impact is minimal as the findings do not change current vaccine efficacy or regulatory status.
Researchers from the University of Geneva and Geneva University Hospitals published a study in Science Translational Medicine identifying why some people experience stronger side effects after mRNA COVID-19 vaccination. The team monitored 51 healthy individuals who received two doses of an mRNA vaccine and found that those with a more active innate interferon response before vaccination were more likely to develop transient symptoms such as fever, fatigue, and injection-site pain. A second mechanism was identified in an animal model, where acquired immunity after a first dose amplified activation of innate immune cells, notably monocytes, upon subsequent doses. Study leader Arnaud Didierlaurent emphasized that side effect severity is not an indicator of vaccine effectiveness. First author Natacha Madelon noted the role of the interferon-related antiviral defense system. The research was supported by the HUG Private Foundation, the Giorgio Cavaglieri Foundation, and Moderna. The findings could eventually help develop better-tolerated vaccines, and the team plans to investigate whether similar mechanisms apply to other vaccine types.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard